AB SCIENCE |
Market Closed -
Other stock markets
|
After market 01:02:30 pm | |||
| 1.936 EUR | +2.76% |
|
1.939 | +0.15% |
| Apr. 04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
| Apr. 03 | AB Science: reconsideration possible for masitinib in ALS | CF |
| Sales 2023 * | 930K 997K | Sales 2024 * | 990K 1.06M | Capitalization | 96.21M 103M |
|---|---|---|---|---|---|
| Net income 2023 * | -19M -20.37M | Net income 2024 * | -18M -19.3M | EV / Sales 2023 * | 103 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 97.2 x |
| P/E ratio 2023 * |
-4.96
x | P/E ratio 2024 * |
-5.23
x | Employees | 89 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on AB Science
More press releases
More news
| 1 day | +2.44% | ||
| 1 week | -1.93% | ||
| Current month | -23.72% | ||
| 1 month | -25.91% | ||
| 3 months | -49.87% | ||
| 6 months | -13.45% | ||
| Current year | -45.71% |
1 week
1.88
2.03
1 month
1.882.68
Current year
1.554.47
1 year
1.556.54
3 years
1.5516.68
5 years
1.5521.75
10 years
1.5521.75
| Managers | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Laurent Guy
DFI | Director of Finance/CFO | - | 01-12-31 |
| Chief Tech/Sci/R&D Officer | - | 18-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Patrick Moussy
BRD | Director/Board Member | - | 01-07-10 |
| Director/Board Member | 62 | 21-06-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.936 | +2.76% | 32 531 |
| 24-04-25 | 1.884 | -2.89% | 71,388 |
| 24-04-24 | 1.94 | -2.02% | 68,439 |
| 24-04-23 | 1.98 | -0.90% | 57,815 |
| 24-04-22 | 1.998 | +1.52% | 75,972 |
Real-time Euronext Paris, April 26, 2024 at 07:27 am EDT
More quotes
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q4 2023 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.884
EUR
Average target price
6.895
EUR
Spread / Average Target
+265.98%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -45.71% | 103M | |
| +4.86% | 69.91B | |
| +10.97% | 9.03B | |
| -17.03% | 4.75B | |
| +37.51% | 4.31B | |
| +3.92% | 3.88B | |
| +17.72% | 2.37B | |
| -24.13% | 2.26B | |
| -29.70% | 2.2B | |
| +9.09% | 1.98B |
- Stock Market
- Equities
- AB Stock
